Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction

Hypertension

Volumn 55, Issue 2, 2010, Pages 241-248

  Solomon, Scott D ^a   Verma, Anil ^a   Desai, Akshay ^a   Hassanein, Amira ^a   Izzo, Joseph ^b   Oparil, Suzanne ^c   Lacourciere, Yves ^d   Lee, Joleen ^e   Seifu, Yodit ^a   Hilkert, Robert J ^e   Rocha, Ricardo ^e   Pitt, Bertram ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c University of Alabama at Birmingham   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin receptor blocker; Arterial stiffness; Diastolic dysfunction; Echocardiography; Hypertension

Indexed keywords

AMLODIPINE; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAM; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE RELAXATION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 74949086153     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.138529     Document Type: Article

References (22)

1. Frohlich ED. The heart in hypertension: unresolved conceptual challenges. Hypertension. 1988;11:I19-I24.
2. López B, González A, Varo N, Laviades C, Querejeta R, Díez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001;38:1222-1226.
3. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension. 2001;38:588-591.
4. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA. 2003;289:194-202.
5. Zile M, Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: I-diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393. (Pubitemid 34260433)
6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
7. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; for the Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-2087
8. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. US Department of Health and Human Services. Available at: www.nhlbi.nih. gov/guidelines/ hypertension/jnc7full.pdf. Accessed November 22, 2009.
9. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S; for the American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
10. Hassanein A, Desai A, Verma A, Oparil S, Izzo J, Rocha R, Hilkert R, Seifu Y, Pitt B, Solomon SD. EXCEED: exforge(R)-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. Ther Adv Cardiovasc Dis; Epub ahead of print July 28, 2009.
11. Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD; for the VALIDD Investigators. Rationale and design: the Valsartan in Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006;152:246-252.
12. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102:1788-1794.
13. Ho CY, Solomon SD. A clinician's guide to tissue Doppler imaging. Circulation. 2006;113:e396-e398.
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; for the Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardi-ography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
15. Omboni S, Riva I, Giglio A, Caldara G, Groppelli A, Parati G. Validation of the Omron M5-I, R5-I and HEM-907 automated blood pressure monitors in elderly individuals according to the International Protocol of the European Society of Hypertension. Blood Press Monit. 2007;12:233-242. (Pubitemid 47356409)
16. Ishikawa J, Kario K, Morinari M, Hoshide S, Eguchi K, Miyashita H, Shimada K. Reproducibility of semi-automatic radial augmentation index (HEM-9101, Omron) and the correlation to the carotid augmentation index in patients with hypertension. Am J Hypertens. 2005;18:A34.
17. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res. 2007;30:219-228.
18. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002;105:1928-1933.
19. Ouzounian M, Lee DS, Liu P. Diastolic heart failure: mechanism and controversies. Nat Clin Pract Cardiovasc Med. 2008;5:375-386.
20. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
21. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36:312-318.
22. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; for the CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113:1213-1225.